Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Phase II trial of liposomal daunorubicin in malignant pleural mesothelioma
Autore:
Steele, JPC; ODoherty, CA; Shamash, J; Evans, MT; Gower, NH; Tischkowitz, MD; Rudd, RM;
Indirizzi:
St Bartholomews Hosp, Dept Med Oncol, London EC1A 7BE, England St Bartholomews Hosp London England EC1A 7BE l, London EC1A 7BE, England Royal Free & Univ Coll Med Sch, London Lung Canc Grp, London, England Royal Free & Univ Coll Med Sch London England Canc Grp, London, England
Titolo Testata:
ANNALS OF ONCOLOGY
fascicolo: 4, volume: 12, anno: 2001,
pagine: 497 - 499
SICI:
0923-7534(200104)12:4<497:PITOLD>2.0.ZU;2-H
Fonte:
ISI
Lingua:
ENG
Keywords:
liposomal daunorubicin; malignant pleural mesothelioma; phase II trial;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Life Sciences
Citazioni:
8
Recensione:
Indirizzi per estratti:
Indirizzo: Steele, JPC St Bartholomews Hosp, Dept Med Oncol, London EC1A 7BE, EnglandSt Bartholomews Hosp London England EC1A 7BE 1A 7BE, England
Citazione:
J.P.C. Steele et al., "Phase II trial of liposomal daunorubicin in malignant pleural mesothelioma", ANN ONCOL, 12(4), 2001, pp. 497-499

Abstract

Background: To assess the response rate, toxicity and survival in patientswith malignant pleural mesothelioma treated with liposomal daunorubicin. The study design allowed for dose escalation pending toxicity. Patients and methods: Liposomal daunorubicin (DaunoXome, Nexstar, USA) 120mg/m(2) was administered every 21 days to a maximum of 6 cycles. Patients had to have histologically-proven malignant pleural mesothelioma. Patients were all chemotherapy-naive with ECOG performance status 0-2. Results: Fourteen patients were enrolled. There were no objective or symptomatic responses though nine patients (64%) had stable disease on therapy. Myelosuppression was the major toxicity with 9 of 11 patients evaluable fortoxicity experiencing grade 3 or 4 neutropenia. Other toxicities seen in at least 30% of patients included grade 3 infection and grade 2 nausea and vomiting. The median overall survival by intention-to-treat analysis was 6.1months from the time of first treatment. The median duration of stable disease from time of first treatment for patients not progressing on therapy was 5.1 months. Conclusions: Liposomal daunorubicin 120 mg/m(2) has no useful clinical activity in patients with malignant pleural mesothelioma. Toxicity was substantial with most patients experiencing at least one episode of grade 3 or 4 neutropenia. Liposomal daunorubicin cannot be recommended for patients with malignant pleural mesothelioma.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 29/11/20 alle ore 00:17:46